Ani pharmaceuticals announces launch of aspirin and extended release dipyridamole capsules, 25mg/200mg

Ani pharmaceuticals, inc. announced the launch of aspirin and extended release dipyridamole capsules, 25mg/200mg (the generic equivalent of aggrenox®). this launch represents ani's fifth generic product introduction in 2019. ani acquired the rights to launch this drug in an acquisition executed in 2018. as part of that acquisition, ani entered into a supply agreement for aspirin and extended release dipyridamole capsules whereby ani receives drug product, packaged in the ani label, starting on october 1, 2019 and ending no later than march 1, 2021. ani estimates that the current annual u.s. market for aspirin and extended release dipyridamole capsules is approximately $80 million, based on iqvia data. there are currently six suppliers of this drug in the u.s. market. aspirin and extended-release dipyridamole capsules are indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis.
ANIP Ratings Summary
ANIP Quant Ranking